Is EXEL or FATE more undervalued in 2026?

CirclFi compares Exelixis, Inc. (EXEL) and Fate Therapeutics, Inc. (FATE) using 13 institutional-grade valuation models. EXEL has a Quality of Company score of 10.0/10 while FATE scores 5.5/10.

Which is a better buy — EXEL or FATE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EXEL and FATE valuations compare?

EXEL at $51.45 and FATE at $2.63 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EXEL vs FATE Valuation Comparison 2026 — Intrinsic Value Analysis

EXEL

Biotechnology

Exelixis, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$51.45

Last close

Models

12/13

Active

FATE

Biotechnology

Fate Therapeutics, Inc.

Quality

5.5

out of 10

Value Trap

SAFE

Price

$2.63

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	EXEL Fair Value	EXEL Upside	FATE Fair Value	FATE Upside
Bayesian DCF	Intrinsic	$43.90	-14.7%	$0.62	-76.3%
Earnings Power Value	Intrinsic	$29.37	-42.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$44.22	-14.1%	$0.18	-88.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EXEL vs FATE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EXEL vs FATE — Which Stock Is More Undervalued?

EXEL scores higher with a 10.0/10 quality rating vs FATE's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Exelixis, Inc. (EXEL) and Fate Therapeutics, Inc. (FATE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EXEL currently trades at $51.45 with a QOC of 10.0/10, while FATE trades at $2.63 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).